

B15  
6. (Once Amended) The antibody of claim 4, further characterized as having the specificity of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

B16  
8. (Once Amended) The antibody of claim 2, wherein the antibody is humanized.

B17  
Anb CS  
10. (Once Amended) The antibody of claim 9, which preferentially binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1), or an eight amino acid epitope having an analog sequence of the sequence QSRDTEVL (SEQ ID NO: 1), of the ECRTP/DEP-1 ectodomain.

B18  
12. (Once Amended) The antibody of claim 8, wherein the humanized antibody is further characterized as having the specificity of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

B19  
13. (Once Amended) The antibody of claim 12, where the humanized antibody is a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

14. (Once Amended) The antibody of claim 2, in a pharmaceutically acceptable diluent or excipient.

B20  
Please add the following new claims:  
3  
45. (New) The antibody of claim 2, which has activity in the modulation of angiogenesis.

46. (New) The antibody of claim 8, which has activity in the modulation of angiogenesis.

47. (New) The antibody of claim 2, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')2 fragment and an F(v) fragment.

48. (New) The antibody of claim 47, wherein the F(v) fragment is an scFv fragment.

49. (New) The antibody of claim 4, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')2 fragment and an F(v) fragment.

50. (New) The antibody of claim 49, wherein the F(v) fragment is an scFv fragment.

51. (New) The antibody of claim 8, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab'fragment, an F(ab')2 fragment and an F(v) fragment.

52. (New) The antibody of claim 51, wherein the F(v) fragment is an scFv fragment.

53. (New) The antibody of claim 3, which binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1).

54. (New) The antibody of claim 10, which binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1).

55. (New) An antibody having the specificity of an antibody produced by the hybridoma cell line having ATCC accession number HB12570.